VNDA Vanda Pharmaceuticals Inc.
XNAS
3.94
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VNDA
$3.94
—
Key stats
$3.94
Pre-market
$3.99
+1.27%
- 52-Week Range
- $3.88 – $9.94
- YTD
- -52.24%
- IV Rank (30D)
- 38.55
- Straddle Price
- $0.75
- P/C Vol Ratio
- 0.91
- Market Cap
- $0.2B
- Open
- $4.00
- Day Range
- $3.92 – $4.11
- Volume
- 810,903
- Prev Close
- $4.01
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.71 |
| Cost of Equity (CAPM) | 8.49% (VRP-adj) |
| WACC | 8.58% |
| Volatility Risk Premium | +173.8pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -1.7% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -124.8% |
| Book / Price | 120.5% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 93.3% |
| FCF Margin (TTM) | -65.7% |
| Debt / Equity | 0.01 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $4.91 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $4.39 |
| Bollinger Width / SMA20 | 658.0% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: ACAD, LFST, PFE
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
89%
20-Day Fair Value
≈ by Nov 25, 2026
$3.97
α +0.7%
rank 96%
conviction
45%
40-Day Fair Value
≈ by Dec 24, 2026
$4.03
α +2.2%
rank 96%
conviction
70%
60-Day Fair Value
≈ by Jan 22, 2027
$4.09
α +3.9%
rank 95%
conviction
89%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 32.4× · 3 peers |
| Peer P/B | $12.35 | 16% | median 2.6× · 3 peers |
| Peer P/S | $11.01 | 16% | median 3.0× · 3 peers |
| Market Anchor (SMA50) | $4.91 | 68% | stability 84% (BB-width) |
| Options Expected (B-L 30d) | $3.64 | 0% | 5 strikes · skew +0.35 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.2B
- Employees
- 533
- List Date
- 2006-04-12
- CIK
- 0001347178
- Next Earnings
- 2026-10-28 (After-Close)
- EPS Forecast
- ($0.72) (3 est.)
- Headquarters
- Washington, DC
- Homepage
- https://www.vandapharma.com
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 5.13% | -8.40% | 3.50% | -20.35% | -8.51% | -8.61% | -6.21% |
| Feb | 27.65% | -25.31% | -16.04% | 19.84% | 10.44% | 15.12% | 5.28% |
| Mar | -19.85% | -0.35% | 5.27% | -10.85% | -2.75% | -15.42% | -7.33% |
| Apr | 5.67% | -16.15% | -10.23% | 15.53% | 0.22% | 0.42% | -0.76% |
| May | 3.75% | -3.82% | -7.47% | 7.13% | -2.25% | -7.86% | -1.75% |
| Jun | 20.77% | 11.79% | 11.69% | 10.35% | 9.77% | -3.85% | 10.09% |
| Jul | -23.32% | -3.66% | -10.11% | 4.66% | -8.97% | -15.07% | -9.41% |
| Aug | -1.01% | 0.38% | -7.98% | -6.21% | 12.89% | 3.25% | 0.22% |
| Sep | 1.60% | -8.60% | -15.46% | -7.68% | 5.94% | -9.41% | -5.60% |
| Oct | -3.71% | 3.46% | 5.04% | 2.42% | -14.71% | -18.09%* | -4.26% |
| Nov | -15.98% | 2.54% | -14.87% | 10.52% | 19.91% | -- | 0.42% |
| Dec | -1.63% | -32.57% | 8.21% | -4.96% | 75.70% | -- | 8.95% |
| Total | -12.59% | -61.14% | -42.57% | 13.31% | 106.71% | -48.49% | -7.46% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $4.39
SMA 50: $4.91
SMA 200: $6.28
Current: $3.94
EMA 12: $4.18
EMA 26: $4.46
MACD: -0.2765 | Signal: -0.0219
BEARISH
ADX (14): 39.13
TREND
+DI: 11.69
−DI: 28.68
Momentum Oscillators
RSI (14): 26.63
OVERSOLD
Stoch %K: 13.13
Stoch %D: 12.43
Williams %R: -91.50
Volume & Volatility
BB Upper: $5.02
BB Lower: $3.75
NEUTRAL
OBV: 43,235,985
Vol SMA 20: 1,137,353
Vol ROC: 55.92%
ATR: $0.19
True Range: $0.19
HV 20: 33.8%
HV 30: 34.3%
HV 60: 38.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report - VNDA
Executive Summary
Overall assessment: NEUTRAL with confidence level (6/10)
Key drivers:
- Recent news sentiment has been mixed, with both positive and negative headlines impacting the stock price.
- Technical indicators show a range-bound market, with no clear trend direction.
Primary risks:
- High volatility, as measured by beta (1.11) and historical volatility (HV30 58.6%).
- Mixed signals from recent news headlines, which may lead to whipsaws in the short term.
Investment thesis: VNDA is a stock in a range-bound market, with no clear trend direction. The recent mixed news sentiment has contributed to this uncertainty. While there are potential catalysts in the pipeline, such as earnings reports and clinical trial results, the current volatility and lack of direction make it challenging to predict the short-term trajectory.
Recent news sentiment impact: The positive headlines on 2024-06-07 and 2024-05-16 have contributed to a short-term bounce, while the negative headline on 2025-08-01 has led to some weakness. The overall sentiment is NEUTRAL due to these mixed signals.
Technical Analysis
Trend Direction: Range-bound (1-4 weeks), Medium-term (1-3 months)
Support/Resistance Levels:
- SMA 20: $6.57
- SMA 50: $6.94
- Upper Bollinger Band: $7.53
Momentum Signals: RSI interpretation: Neutral (45.85) MACD signal: Bearish (Histogram: -0.25) Bollinger Bands position: Squeeze, as price touches the middle band.
Volume Analysis:
- Volume SMA 20: 1145681.85
- On-Balance Volume (OBV): 61478629.71
- Volume Rate of Change: -58.34%
News & Sentiment Analysis
Recent Headlines Summary: Mixed news sentiment, with both positive and negative headlines contributing to the stock's volatility.
Sentiment Assessment: Neutral, as the recent news headlines have been mixed in terms of their impact on the stock price.
Catalyst Identification: Earnings reports, clinical trial results, and potential changes in regulatory environments may serve as catalysts for VNDA's stock price.
Market Narrative: The current range-bound market is characterized by mixed signals from technical indicators and news sentiment. This uncertainty makes it challenging to predict the short-term trajectory of the stock price.
Risk & Volatility Assessment
Beta Interpretation: High risk, with a beta value above 1.11 relative to the broader market (SPY).
Volatility Regime: Current volatility is higher than historical levels, as measured by HV30 and HV60.
Options Market Signals:
- IV Rank: 69.6% (Medium)
- Put/Call Volume Ratio: 1.21 (Neutral sentiment)
Downside Protection: Support levels at SMA 20 ($6.57) and the lower Bollinger Band ($5.60) provide some downside protection.
Market Context & Positioning
Sector Performance: VNDA is outperforming its sector peers, with a relative strength of 0.16.
Institutional Activity: Institutional interest has been moderate, as reflected in the volume flow and open interest metrics.
Correlation Analysis: VNDA's stock price moves inversely to the broader market (R-squared interpretation).
Relative Valuation: VNDA is trading within a range, with no clear overvaluation or undervaluation relative to its peers.
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $6.57
- Upper Bollinger Band: $7.53
Breakout/Breakdown Levels: None identified in the current technical setup.
Time-Sensitive Catalysts: Earnings reports and clinical trial results may serve as catalysts for VNDA's stock price.
Risk Management: A stop-loss level at SMA 20 ($6.57) provides some downside protection, while position sizing considerations should be made based on the current volatility regime.
By considering both technical and news sentiment analysis, we can better understand the dynamics driving VNDA's stock price. While there are potential catalysts in the pipeline, the current range-bound market and high volatility make it challenging to predict the short-term trajectory. As such, a NEUTRAL confidence level is warranted.
Generated
News
All VNDA news →
Earnings History
17 of 22 under expected move
Avg Expected Move
15.95%
Avg Actual Move
8.41%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-10 | After-Close | 12.20% | 21.16% | 1.73x | Exceeded |
| 2021-05-05 | After-Close | 7.90% | 5.61% | 0.71x | Within |
| 2021-07-28 | After-Close | 8.19% | 8.50% | 1.04x | Exceeded |
| 2021-11-03 | After-Close | 14.43% | 14.05% | 0.97x | Within |
| 2022-02-23 | After-Close | 19.74% | 2.60% | 0.13x | Within |
| 2022-05-05 | After-Close | 19.80% | 2.04% | 0.10x | Within |
| 2022-08-03 | After-Close | 7.87% | 4.63% | 0.59x | Within |
| 2023-02-08 | After-Close | 10.49% | 0.84% | 0.08x | Within |
| 2023-05-03 | After-Close | 12.83% | 7.51% | 0.59x | Within |
| 2023-07-27 | After-Close | 18.27% | 8.05% | 0.44x | Within |
| 2023-11-08 | After-Close | 12.24% | 21.94% | 1.79x | Exceeded |
| 2024-02-07 | After-Close | 14.56% | 11.81% | 0.81x | Within |
| 2024-05-08 | After-Close | 13.25% | 6.53% | 0.49x | Within |
| 2024-07-31 | After-Close | 11.56% | 3.42% | 0.30x | Within |
| 2024-11-06 | After-Close | 24.03% | 2.66% | 0.11x | Within |
| 2025-02-13 | After-Close | 10.11% | 5.96% | 0.59x | Within |
| 2025-05-07 | After-Close | 11.99% | 3.65% | 0.30x | Within |
| 2025-07-31 | After-Close | 61.62% | 1.64% | 0.03x | Within |
| 2025-10-29 | After-Close | 14.79% | 20.15% | 1.36x | Exceeded |
| 2026-02-11 | After-Close | 12.79% | 17.63% | 1.38x | Exceeded |
| 2026-05-06 | After-Close | 15.12% | 14.11% | 0.93x | Within |
| 2026-08-05 | After-Close | 17.19% | 0.49% | 0.03x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
VNDA Options Activity & IV Rank
VNDA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 106.5%
7-DTE IV: —
Expected Move: $0.75
7-DTE Move: $0.75
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 11
Put Volume: 10
P/C Volume: 0.909
NEUTRAL
Call OI: 1,778
Put OI: 175
P/C OI: 0.098
Total OI: 1,953
ATM Options Pricing
ATM Call: $0.35
ATM Put: $0.40
Call %: 8.9%
Put %: 10.2%
Chain Summary
Chain Volume: 612
Chain OI: 9,736
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 72nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
72%
vs own history
GEX tilt
+0.97
OI-weighted, today
Vanna tilt
+0.94
δ-sensitivity to IV
Charm tilt
-0.94
δ-decay vs time
Vanna tilt +0.94: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.94: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 90.1% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)38.5MediumOct 26
Straddle Price (30 DTE)$0.75Oct 26
Beta Analysis
Risk Metrics
Beta: 0.7469
Alpha: -11.75%
Correlation: 0.1163
R-Squared: 1.4%
Stock Volatility: 81.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own VNDA
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $21.1M | #676 of 3138 | -8.5% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $9.8M | #1587 of 3716 | -14.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $4.6M | #2162 of 6285 | +19.7% | 13F | |
| Point72 Hedge fund Steve Cohen | $1.9M | #1288 of 1945 | +92.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $3K | #4350 of 4729 | -58.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
VNDA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 59,118,901 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$2.18M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $1.10M | 50.29% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $587.52K | 26.96% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $436.97K | 20.05% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $58.75K | 2.70% | 2026-06-30 |
4 filers$479.81K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $239.29K | 49.87% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $126.68K | 26.40% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $101.59K | 21.17% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $12.24K | 2.55% | 2026-06-30 |
VNDA Insider Trading (Form 4)
Latest: 2026-06-08Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | Anne Sempowski Ward | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Richard W Dugan | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Tage Honore | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Phaedra Chrousos | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Stephen Ray Mitchell | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Charles Cliff Duncan | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Daniel Patrick McGuire | SVP, GC and Secretary | Award (A) | +80,000 | — | EDGAR | |
| 2026-05-20 | Stephen Ray Mitchell | Director | Gift (G) | −25,836 | — | EDGAR | |
| 2026-04-24 | Charles Cliff Duncan | Director | Award (A) | +57,101 | — | EDGAR | |
| 2026-03-04 | Mihael Hristos Polymeropoulos | President and CEO | Sell (S) | −156,235 | $8.17 | -$1.28M | EDGAR |
| 2026-03-04 | Timothy Williams | SVP & General Counsel | Sell (S) | −42,434 | $8.27 | -$350.8K | EDGAR |
| 2026-03-04 | Gunther Birznieks | SVP, Business Development | Sell (S) | −42,431 | $8.27 | -$350.7K | EDGAR |
| 2026-03-04 | Joakim Wijkstrom | SVP, Chief Marketing Officer | Sell (S) | −30,800 | $8.27 | -$254.6K | EDGAR |
| 2026-03-04 | Kevin Patrick Moran | SVP, CFO & Treasurer | Sell (S) | −42,442 | $8.27 | -$350.8K | EDGAR |
| 2026-02-24 | Tage Honore | Director | Sell (S) | −30,000 | $8.03 | -$240.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VNDA Insider Holdings
12 insiders · @ $3.94
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Mihael Hristos Polymeropoulos | President and CEO | 2,704,496 | $10.66M | -$27.73M | 76 | 2026-03-04 |
| 2 | Gunther Birznieks | SVP, Business Development | 494,197 | $1.95M | -$2.02M | 20 | 2026-03-04 |
| 3 | Kevin Patrick Moran | SVP, CFO & Treasurer | 412,015 | $1.62M | -$1.05M | 19 | 2026-03-04 |
| 4 | Timothy Williams | SVP & General Counsel | 377,450 | $1.49M | -$1.55M | 22 | 2026-03-04 |
| 5 | Joakim Wijkstrom | SVP, Chief Marketing Officer | 333,469 | $1.31M | -$706.5K | 17 | 2026-03-04 |
| 6 | Richard W Dugan | Director | 219,054 | $863.1K | -$556.6K | 25 | 2026-06-08 |
| 7 | Phaedra Chrousos | Director | 164,950 | $649.9K | -$40.1K | 10 | 2026-06-08 |
| 8 | Anne Sempowski Ward | Director | 160,667 | $633.0K | $0 | 8 | 2026-06-08 |
| 9 | Tage Honore | Director | 135,069 | $532.2K | -$240.9K | 6 | 2026-06-08 |
| 10 | Stephen Ray Mitchell | Director | 112,846 | $444.6K | -$540.0K | 15 | 2026-06-08 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VNDA Board & Officers
As of SEC filings through Jun 8, 2026Directors 7
- Mihael Hristos Polymeropoulos · since Apr 12, 2006
- Richard W Dugan · since Apr 12, 2006
- Phaedra Chrousos · since Apr 23, 2019
- Anne Sempowski Ward · since Oct 28, 2019
- Stephen Ray Mitchell · since Feb 14, 2020
- Tage Honore · since Mar 15, 2023
- Charles Cliff Duncan · since Apr 22, 2026
Officers 7
- Mihael Hristos Polymeropoulos · President and CEO · listed since Feb 2023
- Kevin Patrick Moran · SVP, CFO & Treasurer · listed since Jul 2020
- Joakim Wijkstrom · SVP, Chief Marketing Officer · since Aug 19, 2019
- Scott Laverne Howell · VP and Chief People Officer · since Apr 1, 2026
- Daniel Patrick McGuire · SVP, GC and Secretary · since Jun 4, 2026
- Gunther Birznieks · SVP, Business Development · since Mar 23, 2017
- Christos Vasilios Mihael Polymeropoulos · Senior VP, Medical Director · since Apr 1, 2026
Changes in the last 10 years (22)
| Jun 4, 2026 | Daniel Patrick McGuire became SVP, GC and Secretary |
| Apr 22, 2026 | Charles Cliff Duncan became a director |
| Apr 1, 2026 | Scott Laverne Howell became VP and Chief People Officer |
| Apr 1, 2026 | Christos Vasilios Mihael Polymeropoulos became Senior VP, Medical Director |
| Mar 29, 2026 | The company announced the departure of Timothy Williams as SVP & General Counsel in an SEC filing |
| Mar 15, 2023 | Tage Honore became a director |
| Feb 21, 2023 | Mihael Hristos Polymeropoulos first listed as President and CEO in an SEC filing |
| Mar 2, 2022 | Mihael Hristos Polymeropoulos no longer listed as President and CEO in SEC filings |
| Feb 28, 2022 | The company announced the departure of Thomas Watkins from the board in an SEC filing |
| Feb 28, 2022 | The company announced the departure of Aranthan Jones II as Chief Corp. Affairs Officer in an SEC filing |
| Jul 29, 2020 | Kevin Patrick Moran listed as SVP, CFO & Treasurer (previously VP, Acting CFO & Treasurer) in SEC filings |
| Mar 15, 2020 | Kevin Patrick Moran became VP, Acting CFO & Treasurer |
| Feb 14, 2020 | Stephen Ray Mitchell became a director |
| Oct 28, 2019 | Anne Sempowski Ward became a director |
| Aug 19, 2019 | Joakim Wijkstrom became SVP, Chief Marketing Officer |
| Aug 19, 2019 | Aranthan Jones II became Chief Corp. Affairs Officer |
| Apr 23, 2019 | Phaedra Chrousos became a director |
| Aug 13, 2018 | Timothy Williams became SVP & General Counsel |
| Mar 23, 2017 | Gunther Birznieks became SVP, Business Development |
| Mar 3, 2017 | James Patrick Kelly listed as EVP & Chief Financial Officer (previously SVP, CFO, Sec & Treasurer) in SEC filings |
| Jan 5, 2017 | Richard L. Gulino listed as SVP, General Counsel & Sec. (previously SVP & General Counsel) in SEC filings |
| Jan 5, 2017 | Gian Piero Reverberi listed as SVP & Chief Commercial Officer (previously SVP, General Manager Europe) in SEC filings |
Not reported recently (7)
- James Patrick Kelly · Last reported as EVP & Chief Financial Officer in an SEC filing dated Mar 4, 2020
- Gian Piero Reverberi · Last reported as SVP & Chief Commercial Officer in an SEC filing dated Mar 4, 2020
- Michael F Cola · Last reported as a director in an SEC filing dated Jun 17, 2019
- Vincent Milano · Last reported as a director in an SEC filing dated Jun 15, 2018
- Richard L. Gulino · Last reported as SVP, General Counsel & Sec. in an SEC filing dated Mar 2, 2018
- Kenneth Bate · Last reported as a director in an SEC filing dated Jun 19, 2017
- Paolo Baroldi · Last reported as SVP & Chief Medical Officer in an SEC filing dated Jan 5, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
VNDA Proposed Insider Sales (Form 144)
Latest: 2026-03-02
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Timothy Williams | SVP & General Counsel | 42,434 | $350.8K | 2026-03-02 | Merrill Lynch | — | EDGAR |
| 2026-03-02 | Gunther Birznieks | SVP, Business Development | 42,431 | $350.7K | 2026-03-02 | Merrill Lynch | — | EDGAR |
| 2026-03-02 | Joakim Wijkstrom | SVP, Chief Marketing Officer | 30,800 | $254.6K | 2026-03-02 | Merrill Lynch | — | EDGAR |
| 2026-03-02 | Mihael H. Polymeropoulos | Officer, Chairman of the Board | 156,235 | $1.28M | 2026-03-02 | Merrill Lynch | — | EDGAR |
| 2026-03-02 | Kevin Moran | SVP, CFO & Treasurer | 42,442 | $350.8K | 2026-03-02 | Merrill Lynch | — | EDGAR |
| 2026-02-23 | Honore Tage | Director | 30,000 | $240.9K | 2026-02-23 | Merrill Lynch | — | EDGAR |
| 2025-06-13 | Mitchell Stephen Ray | Director | 7,000 | $32.2K | 2025-06-13 | Merrill Lynch | — | EDGAR |
| 2024-11-14 | Mitchell Stephen Ray | Director | 5,000 | $27.0K | 2024-11-14 | Merrill Lynch | — | EDGAR |
| 2024-07-29 | Moran Kevin Patrick | Officer | 2,251 | $13.3K | 2024-07-29 | Merrill Lynch | — | EDGAR |
| 2024-03-04 | Williams Timothy | Officer | 32,025 | $147.6K | 2024-03-04 | Merrill Lynch | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
53 ETFs hold VNDA
25 shown · $44.07M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $8.7M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.07% | $7.6M | $10.4B | 2026-10-23 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $5.5M | $74.6B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $3.5M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $2.1M | $13.9B | 2026-10-23 |
| 6 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.8M | — | 2026-05-31 |
| 7 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $1.8M | — | 2026-10-23 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.02% | $1.7M | $10.7B | 2026-10-23 |
| 9 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.01% | $1.6M | — | 2026-10-23 |
| 10 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.6M | — | 2026-09-30 |
| 11 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $1.1M | — | 2026-10-23 |
| 12 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.01% | $940,092 | $6.6B | 2026-10-23 |
| 13 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $862,731 | — | 2026-09-30 |
| 14 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.01% | $794,706 | — | 2026-10-23 |
| 15 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.06% | $674,646 | $1.2B | 2026-10-23 |
| 16 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $569,961 | — | 2026-07-31 |
| 17 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.02% | $539,084 | $3.2B | 2026-10-23 |
| 18 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $477,330 | $96.5B | 2026-10-23 |
| 19 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.24% | $392,966 | — | 2026-05-31 |
| 20 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.03% | $337,638 | $1.0B | 2026-10-23 |
| 21 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.12% | $336,916 | — | 2026-05-31 |
| 22 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.05% | $296,712 | — | 2026-10-26 |
| 23 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $280,335 | — | 2026-10-23 |
| 24 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $263,315 | — | 2026-05-31 |
| 25 | HAPS Harbor Human Capital Factor US Small Cap ETF | Nport | 0.15% | $262,390 | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-4.05
TTM Revenue
$217.78M
TTM Net Income
$-239.55M
TTM Op. Cash Flow
$-126.51M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $51.72M | $-48.57M | $-0.82 | $-50.22M |
| Q4 '25 | 2025-12-31 | $57.22M | $-141.19M | $-2.39 | $-29.42M |
| Q3 '25 | 2025-09-30 | $56.26M | $-22.59M | $-0.38 | $-31.63M |
| Q2 '25 | 2025-06-30 | $52.59M | $-27.21M | $-0.46 | $-15.25M |
| Q1 '25 | 2025-03-31 | $50.04M | $-29.49M | $-0.50 | $-33.15M |
| Q4 '24 | 2024-12-31 | $53.19M | $-4.91M | $-0.09 | $-1.82M |
| Q3 '24 | 2024-09-30 | $47.65M | $-5.32M | $-0.09 | $-14.58M |
| Q2 '24 | 2024-06-30 | $50.47M | $-4.52M | $-0.08 | $-6.93M |
| Q1 '24 | 2024-03-31 | $47.46M | $-4.15M | $-0.07 | $7.57M |
| Q4 '23 | 2023-12-31 | $45.27M | $-2.40M | $-0.05 | $-3.73M |
| Q3 '23 | 2023-09-30 | $38.81M | $137.00K | — | $-2.05M |
| Q2 '23 | 2023-06-30 | $46.06M | $1.52M | $0.03 | $-13.22M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-07
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.83
P/S
1.07
EV/EBITDA
—
EV/Sales
0.84
ROE
-85.3%
ROA
-55.3%
Div Yield
0.00%
FCF Yield
-54.31%
Debt/Equity
0.01
Current Ratio
—
Market Cap
$232.93M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.83M
SI % of Float
14.48%
Days to Cover
6.45
Short Vol Ratio
55.8%
Free Float
54.08M
Float %
89.5%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-07